LONDON, April 21 (Reuters) – Pfizer may come back to
bid for British drug company AstraZeneca after its
reported 60 billion pound ($101 billion) takeover approach was
rejected, since a deal could make sense for the U.S.
pharmaceuticals giant as it seeks to build up its cancer
In addition to adding promising – though still risky -
experimental medicines known as immunotherapies that boost the
body’s immune system to fight tumours, acquiring AstraZeneca
could also generate significant cost savings, according to
LONDON (Reuters) – Drugmaker GlaxoSmithKline (GSK.L: Quote, Profile, Research, Stock Buzz) – hit by bribery claims in five countries – is to employ hundreds more doctors as members of staff as it seeks to build a new sales model designed to eliminate sharp marketing practices.
Following a decision to cut commercial ties with outside doctors, GSK expects to increase its in-house team of physicians by 10-20 percent over the next year or so from around 1,500 at present, Chief Medical Officer James Shannon told Reuters.